David Abrams’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.22M Hold
1,270,504
0.13% 10
2026
Q1
$5.45M Sell
1,270,504
-2,541,009
-67% -$14.2M 0.12% 10
2025
Q4
$34.2M Hold
3,811,513
0.6% 11
2025
Q3
$14.1M Hold
3,811,513
0.23% 12
2025
Q2
$7.43M Hold
3,811,513
0.12% 12
2025
Q1
$6.71M Hold
3,811,513
0.12% 12
2024
Q4
$10.1M Hold
3,811,513
0.16% 12
2024
Q3
$8.73M Hold
3,811,513
0.14% 13
2024
Q2
$11.1M Hold
3,811,513
0.22% 13
2024
Q1
$13.9M Hold
3,811,513
0.43% 13
2023
Q4
$5.76M Hold
3,811,513
0.18% 14
2023
Q3
$5.11M Hold
3,811,513
0.17% 15
2023
Q2
$6.86M Hold
3,811,513
0.2% 16
2023
Q1
$6.33M Hold
3,811,513
0.2% 16
2022
Q4
$7.32M Hold
3,811,513
0.26% 16
2022
Q3
$8.54M Hold
3,811,513
0.25% 18
2022
Q2
$12.3M Hold
3,811,513
0.33% 17
2022
Q1
$20M Hold
3,811,513
0.47% 17
2021
Q4
$32.4M Hold
3,811,513
0.71% 16
2021
Q3
$37.9M Hold
3,811,513
0.83% 16
2021
Q2
$35.5M Hold
3,811,513
0.79% 15
2021
Q1
$34M Buy
+3,811,513
New +$42.6M 0.77% 15

Other funds holding NUVB

David Abrams's NUVB Position: Q2 2026 in Review

David Abrams held its Nuvation Bio (NUVB) position steady in Q2 2026 at 1,270,504 shares worth $7.22M. The position accounts for 0.13% of the portfolio, ranked #10.

David Abrams first reported a position in NUVB in Q1 2021 and has held it in 22 quarters since. The position peaked at $37.9M in Q3 2021. 242 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • David Abrams held 1,270,504 shares of Nuvation Bio worth $7.22M as of Q2 2026.
  • David Abrams left its Nuvation Bio share count unchanged in Q2 2026.
  • Nuvation Bio made up 0.13% of David Abrams's portfolio in Q2 2026, its #10 holding.
  • David Abrams first reported a position in Nuvation Bio in Q1 2021 and has held it in 22 quarters since.
  • David Abrams's Nuvation Bio position peaked at $37.9M in Q3 2021.
  • 242 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Abrams Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.